Safety and Immunogenicity of an Egg-Cultivated Quadrivalent Inactivated Split-virion Influenza Vaccine (GC3110A) in Healthy Korean Children: a Randomized, Double-blinded, Active-controlled Phase III Study.
10.3346/jkms.2018.33.e100
- Author:
Jin LEE
1
;
Kyung Yil LEE
;
Jong Hyun KIM
;
Chun Soo KIM
;
Byung Wook EUN
;
Hwang Min KIM
;
Dong Ho KIM
;
Young Jin HONG
;
Young Youn CHOI
;
Dae Sun JO
;
Sang Hyuk MA
;
Jin Han KANG
Author Information
1. Department of Pediatrics, Hanil General Hospital, Seoul, Korea.
- Publication Type:Randomized Controlled Trial ; Original Article
- Keywords:
Quadrivalent Influenza Vaccine;
Safety;
Immunogenicity;
Healthy Children
- MeSH:
Adolescent;
Antibody Formation;
Child*;
Hemagglutination;
Humans;
Influenza Vaccines*;
Influenza, Human*;
Seasons;
Seroconversion;
World Health Organization
- From:Journal of Korean Medical Science
2018;33(13):e100-
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: The frequency with which the 2 B lineages have been found to cocirculate in a season has been on the rise, which has spurred the need for a quadrivalent influenza vaccine (QIV) to protect against both B lineages. The World Health Organization (WHO) recommended that QIV include both B lineages beginning in the 2013–2014 flu season. This study was conducted to evaluate the immunogenicity and safety of an egg-cultivated QIV in healthy Korean children and adolescents aged ≥ 6 months to < 19 years. METHODS: A total of 528 subjects were randomized 4:1 to receive either a QIV (GC3110A) or a trivalent influenza vaccine. Hemagglutination inhibition antibody responses were assessed 28 days after the last dose. Safety was also evaluated. RESULTS: The proportion of subjects in the GC3110A group who achieved seroconversion was confirmed to exceed 40% across all age groups. The proportion of subjects aged ≥ 6 months to < 3 years in the GC3110A group who achieved seroprotection failed to meet the Ministry of Food and Drug Safety (MFDS) standard of 70%. Potential causes may include the small number of subjects, as well as the small dosage. However, results pertaining to the other age groups satisfied the MFDS standard. The safety profile was also comparable to that of the control. CONCLUSION: The new quadrivalent split influenza vaccine may offer broader protection to children and adolescents aged ≥ 3 years to < 19 years of age against both influenza B lineages than the existing trivalent influenza vaccines (Registered at the ClinicalTrials.gov NCT02541253).
